Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Pharmacotherapy

Current role of β-blockers after MI in patients without HF

Nature Reviews Cardiology volume 13, pages 699–700 (2016)Cite this article

Subjects

When administered in the setting of an acute myocardial infarction, β-blockers decrease myocardial ischaemia, reduce the rates of reinfarction and serious ventricular tachyarrhythmias, and have substantial early benefits. However, the benefits of prolonged β-blockade after acute myocardial infarction are unproven and are discussed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Roberts, R. et al. Immediate versus deferred β-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 83, 422–437 (1991).

    Article  CAS  Google Scholar 

  2. Yusuf, S., Wittes, J. & Friedman, L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA 260, 2088–2093 (1988).

    Article  CAS  Google Scholar 

  3. Chatterjee, S. et al. Early intravenous beta-blockers in patients with acute coronary syndrome — a meta-analysis of randomized trials. Int. J. Cardiol. 168, 915–921 (2013).

    Article  Google Scholar 

  4. Amsterdam, E. A. et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 64, e139–e228 (2014).

    Article  Google Scholar 

  5. Roffi, M. et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 37, 267–315 (2016).

    Article  CAS  Google Scholar 

  6. Puymirat, E. et al. β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ 354, i4801 (2016).

    Article  Google Scholar 

  7. Bangalore, S. et al. Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. Am. J. Med. 127, 939–953 (2014).

    Article  CAS  Google Scholar 

  8. Motivala, A. A. et al. Predictors, trends, and outcomes (among older patients ≥65 years of age) associated with beta-blocker use in patients with stable angina undergoing elective percutaneous coronary intervention: insights from the NCDR registry. JACC Cardiovasc. Interv. 9, 1639–1648 (2016).

    Article  Google Scholar 

  9. Packer, M. et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344, 1651–1658 (2001).

    Article  CAS  Google Scholar 

  10. Yancy, C. W. et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 128, 1810–1852 (2013).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Debabrata Mukherjee is at the Department of Internal Medicine, Texas Tech University Health Sciences Center, 4800 Alberta Avenue, El Paso, Texas 79905, USA.,

    Debabrata Mukherjee

  2. Department of Internal Medicine, Division of Cardiovascular Medicine, Kim A. Eagle is at the University of Michigan Frankel Cardiovascular Center, University of Michigan, 1500 East Medical Center Drive, Suite 2131, Ann Arbor, Michigan 48109, USA.,

    Kim A. Eagle

Authors
  1. Debabrata Mukherjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kim A. Eagle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kim A. Eagle.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mukherjee, D., Eagle, K. Current role of β-blockers after MI in patients without HF. Nat Rev Cardiol 13, 699–700 (2016). https://doi.org/10.1038/nrcardio.2016.176

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2016.176

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing